FDA Must Revisit MiMedx Wound Care Powder Classification
A Georgia federal judge vacated the Food and Drug Administration's classification of biomedical company MiMedx's wound care treatment as a biological product, which carries heightened regulatory requirements, finding the agency's determination...To view the full article, register now.
Already a subscriber? Click here to view full article